No Cover Image

Journal article 40 views 9 downloads

Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events / Elinor Lee‐Lane, Fatemeh Torabi, Arron Lacey, Beata Fonferko-Shadrach, Daniel Harris, Ashley Akbari, Ronan Lyons, Mark Rees, Inder Sawhney, Julian Halcox, Robert Powell, Owen Pickrell

Epilepsia, Volume: 62, Issue: 7, Pages: 1604 - 1616

Swansea University Authors: Fatemeh Torabi, Arron Lacey, Beata Fonferko-Shadrach, Ashley Akbari, Ronan Lyons, Mark Rees, Inder Sawhney, Julian Halcox, Robert Powell, Owen Pickrell

  • 56988.pdf

    PDF | Version of Record

    © 2021 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License

    Download (832.46KB)

Check full text

DOI (Published version): 10.1111/epi.16930

Abstract

ObjectiveThis study was undertaken to determine whether epilepsy and antiepileptic drugs (including enzyme-inducing and non-enzyme-inducing drugs) are associated with major cardiovascular events using population-level, routinely collected data.MethodsUsing anonymized, routinely collected, health car...

Full description

Published in: Epilepsia
ISSN: 0013-9580 1528-1167
Published: Wiley 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa56988
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: ObjectiveThis study was undertaken to determine whether epilepsy and antiepileptic drugs (including enzyme-inducing and non-enzyme-inducing drugs) are associated with major cardiovascular events using population-level, routinely collected data.MethodsUsing anonymized, routinely collected, health care data in Wales, UK, we performed a retrospective matched cohort study (2003–2017) of adults with epilepsy prescribed an antiepileptic drug. Controls were matched with replacement on age, gender, deprivation quintile, and year of entry into the study. Participants were followed to the end of the study for the occurrence of a major cardiovascular event, and survival models were constructed to compare the time to a major cardiovascular event (cardiac arrest, myocardial infarction, stroke, ischemic heart disease, clinically significant arrhythmia, thromboembolism, onset of heart failure, or a cardiovascular death) for individuals in the case group versus the control group.ResultsThere were 10 241 cases (mean age = 49.6 years, 52.2% male, mean follow-up = 6.1 years) matched to 35 145 controls. A total of 3180 (31.1%) cases received enzyme-inducing antiepileptic drugs, and 7061 (68.9%) received non-enzyme-inducing antiepileptic drugs. Cases had an increased risk of experiencing a major cardiovascular event compared to controls (adjusted hazard ratio = 1.58, 95% confidence interval [CI] = 1.51–1.63, p < .001). There was no notable difference in major cardiovascular events between those treated with enzyme-inducing antiepileptic drugs and those treated with non-enzyme-inducing antiepileptic drugs (adjusted hazard ratio = .95, 95% CI = .86–1.05, p = .300).SignificanceIndividuals with epilepsy prescribed antiepileptic drugs are at an increased risk of major cardiovascular events compared with population controls. Being prescribed an enzyme-inducing antiepileptic drug is not associated with a greater risk of a major cardiovascular event compared to treatment with other antiepileptic drugs. Our data emphasize the importance of cardiovascular risk management in the clinical care of people with epilepsy.
Keywords: cardiovascular risk; enzyme-inducing antiepileptic drugs
College: Swansea University Medical School
Issue: 7
Start Page: 1604
End Page: 1616